Summary: Inflammation is a vital defense mechanism, but when it remains chronically activated it can drive a wide range of diseases, from sepsis to neurodegenerative disorders. A comprehensive review highlights the receptor TREM-1 (Triggering Receptor Expressed on Myeloid cells-1) as a central amplifier of harmful immune responses and an attractive therapeutic target.
TREM-1 is expressed on key myeloid cells such as macrophages, monocytes, and neutrophils. Rather than initiating inflammation, TREM-1 amplifies innate immune signaling, increasing the intensity of the inflammatory response. The review positions TREM-1 as a potential “universal key” for interrupting excessive inflammation across diverse diseases, including rheumatoid arthritis, gout, sepsis, and neurodegenerative conditions.
Key Facts
- The Multiplier Effect: TREM-1 signals through the adaptor protein DAP12 and engages in crosstalk with Toll-like receptors, producing a pronounced escalation of innate immune activation.
- A Marker for Severity: In sepsis, elevated soluble TREM-1 in blood correlates strongly with the intensity of the inflammatory response and with patient outcomes.
- Neuroinflammation and Microglia: TREM-1 expression on microglia links this receptor to progressive neuroinflammation seen in Alzheimer’s and Parkinson’s diseases, suggesting that moderating TREM-1 activity could slow neuron loss.
- Experimental Antagonists: Several TREM-1 inhibitors—LR12, LP17, GF9, and a clinical-stage nanobiotide—have reduced inflammation in preclinical models of joint disease and sepsis.
- Therapeutic Balance: While inhibiting TREM-1 holds promise, researchers caution about the risk of immunosuppression; therapies must blunt harmful hyperinflammation without unduly weakening host defenses.
Source: FAR Publishing Ltd
Published in Current Molecular Pharmacology: A thorough review by Eman R. Al Sawy and colleagues at Cairo University aggregates current evidence that positions TREM-1 as a pivotal amplifier of inflammatory responses. The authors describe TREM-1’s biology, signaling pathways, and its pathologic roles across acute and chronic inflammatory disorders.
According to corresponding author Nesrine S. El Sayed, dysregulated TREM-1 activation contributes to both acute and chronic inflammatory conditions, yet targeted clinical treatments remain scarce. The review synthesizes preclinical and emerging clinical data that support TREM-1 as both a therapeutic target and a biomarker of disease severity.
The review details TREM-1’s involvement in sepsis—where higher soluble TREM-1 associates with worse outcomes—its contribution to inflammatory arthritis, and its role in neurodegenerative disease through microglial activation. Experimental TREM-1 antagonists have demonstrated beneficial effects in animal models, but translation to human therapy will require careful evaluation of species differences, disease heterogeneity, and safety concerns.
The authors conclude that TREM-1-targeted therapies have translational potential for conditions such as sepsis, rheumatoid arthritis, gout, and Alzheimer’s disease. They call for well-designed clinical trials to determine optimal dosing windows and to identify patient subgroups most likely to benefit.
Key Questions Answered:
A: TREM-1 is an evolutionary adaptation that boosts the immune response during severe infection, enabling a rapid and forceful defense. The problem arises when that amplification persists after the threat is removed, contributing to chronic inflammation and tissue damage.
A: Potentially. Because TREM-1 is active in myeloid-lineage cells found in multiple tissues—including joint macrophages and brain microglia—a drug that safely reduces TREM-1 signaling could dampen inflammation across different organs. Clinical evidence is needed to confirm this cross-disease benefit.
A: The field is in a translational stage. Preclinical results are encouraging and at least one nanobiotide has entered clinical development. The critical next steps are human trials that assess efficacy and ensure treatments do not excessively suppress protective immunity.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The referenced journal paper was reviewed in full.
- Additional context was provided by editorial staff for clarity.
About this genetics and neuroinflammation research news
Author: Chris Zhou
Source: FAR Publishing Limited
Contact: Chris Zhou – FAR Publishing Limited
Image: Image credited to Neuroscience News
Original Research: Open access. “TREM-1 receptor: A key player in inflammatory diseases” by Eman R. Al Sawy, Mona M. Saber, Noha N. Nassar, and Nesrine S. El Sayed. DOI: 10.1016/j.cmp.2026.03.002
Abstract
TREM-1 receptor: A key player in inflammatory diseases
Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor predominantly found on myeloid cells—macrophages, monocytes, and neutrophils—where it amplifies innate immune responses. Dysregulated TREM-1 activation has been linked to the pathogenesis of both acute and chronic inflammatory conditions, including sepsis, inflammatory arthritis, and neurodegenerative diseases.
Despite advances in supportive care, targeted therapies that safely moderate runaway inflammation remain limited. Recent preclinical and early clinical evidence support TREM-1 as a promising therapeutic target and suggest soluble TREM-1 may serve as a biomarker for disease severity and prognosis.
This review summarizes current understanding of TREM-1 biology and signaling, outlines its pathogenic roles in sepsis, arthritis, and neurodegeneration, and surveys emerging TREM-1-directed therapeutic strategies with an emphasis on their translational relevance and the challenges that remain for clinical application.